Sol-Gel Technologies Ltd. (SLGL) stock
Close on Nov 11, 2026Market cap $176.64MP/E –Yield –
Sol-Gel Technologies Ltd. grew revenue 68.0% to $19.39M over fiscal 2025. Free cash flow was $275.00K. At the latest close the market valued the company at $176.64M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $176.64M
- P/E ratio
- –
- Price to sales
- 9.11
- Price to book
- 3.67
- Dividend yield
- –
- Free cash flow yield
- 0.16%
Fundamentals
- Revenue
- $19.39M
- Net income
- -$6.13M
- EPS, diluted
- -$2.19
- Free cash flow
- $275.00K
- Book value per share
- $14.71
- Diluted shares
- 3M
Trading
- Previous close
- $61.50
- Open
- $62.99
- Day's range
- $62.00 – $63.72
- Volume
- 16,178
- Average volume (20 days)
- 36,666
- Beta (5 years)
- 1.02
- 52-week range
- $28.81 – $97.97
- RSI (14 days)
- 43.2
- Volatility (1 year)
- 83.0%
- Relative volume
- 0.32×
- WACC
- 10.0%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SLGL | S&P 500 | Difference | SLGL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.7% | -2.4% | −9.3 pts | ||
| 3 months | -18.6% | -1.2% | −17.5 pts | ||
| Year to date | +50.5% | +12.3% | +38.2 pts | ||
| 1 year | +98.9% | +12.4% | +86.4 pts | ||
| 3 years | +359.4% | +78.8% | +280.6 pts | +66.2% | +21.4% |
| 5 years | -30.2% | +75.2% | −105.3 pts | -6.9% | +11.9% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sol-Gel Technologies filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Sol-Gel Technologies
Pharmaceutical Preparations
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on identifying, developing, and commercializing topical therapies for skin conditions. Its commercial portfolio includes Twyneo, an FDA-approved non-antibiotic topical cream for acne vulgaris, and Epsolay, an approved encapsulated benzoyl peroxide cream for papulopustular rosacea. In addition to commercialized treatments, the company is advancing an investigational pipeline that includes SGT-610 (patidegib gel) for preventing basal cell carcinomas in Gorlin syndrome patients and SGT-210 (erlotinib) for localized epidermal growth factor receptor inhibition. Its target customer base consists of patients requiring specialized dermatological medical treatments.
Company profile, executives and historySol-Gel Technologies stock: common questions
What is Sol-Gel Technologies's stock price?
SLGL closed at $63.40 on Nov 11, 2026, up 3.09% on the day. Over the past 52 weeks it traded between $28.81 and $97.97.
What is Sol-Gel Technologies's market cap?
Sol-Gel Technologies was worth $176.64M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SLGL's P/E ratio?
Sol-Gel Technologies lost money over fiscal 2025 (diluted EPS -$2.19), so it has no meaningful P/E ratio.
How much revenue does Sol-Gel Technologies make?
Sol-Gel Technologies reported revenue of $19.39M for fiscal 2025, up 68.0% from a year earlier.
Does Sol-Gel Technologies pay a dividend?
No. Sol-Gel Technologies has not paid a cash dividend over the last twelve months.
How has SLGL stock performed over the past year?
Including dividends, SLGL returned +98.9% over the past year, against +12.4% for the S&P 500.
How many SLGL shares are sold short?
0M shares were sold short at the latest FINRA report, 16.26% of the float, or 3.2 days of average trading volume.
Who are Sol-Gel Technologies's competitors?
Companies most similar to Sol-Gel Technologies by business, industry and size include VRCA, EVFM, BFRI, DERM, ZNTL.
See a number that looks wrong?